Every 10-Q that CytomX Therapeutics, Inc. (CTMX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CTMX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CTMX filings page.
CytomX Therapeutics, Inc. reported Q2 2026 revenue of $1.4 million, down from $18.7 million a year earlier, and a net loss of $20.7 million versus a $0.2 million loss, as large 2025 collaboration revenues from partners such as Bristol Myers Squibb and Astellas were not repeated.
For the first half of 2026, revenue was $11.7 million and the net loss $38.9 million, compared with $69.6 million of revenue and $23.4 million of net income in 2025. Operating expenses rose to $55.1 million from $48.2 million, with higher research and development and general and administrative costs including increased stock‑based compensation.
Liquidity strengthened: at June 30, 2026 cash and cash equivalents were $17.2 million and short‑term U.S. Treasury investments $313.1 million, aided by approximately $234.2 million of net proceeds from a March underwritten equity and pre‑funded warrant offering. Deferred revenue increased to $54.7 million, supported by an expanded Regeneron collaboration that added two new bispecific programs, a $37.0 million upfront payment and potential milestones aggregating up to about $4.0 billion. Varseta‑M showed Phase 1 activity in late‑line metastatic colorectal cancer with confirmed response rates up to 32% and median progression‑free survival up to 7.1 months, and CytomX is preparing registrational planning, combination studies and expansion into additional EpCAM‑expressing tumors, while CX‑801 continues Phase 1 development with Merck’s KEYTRUDA.
CytomX Therapeutics, Inc. reported first-quarter 2026 results showing lower collaboration revenue and a return to net loss while strengthening its balance sheet. Revenue was $10.3 million, down from $50.9 million a year earlier, mainly due to completed and terminated collaborations with Bristol Myers Squibb, Amgen and Astellas.
The company recorded a net loss of $18.2 million, compared with net income of $23.5 million in the prior-year quarter, as revenue fell while research and development and general and administrative expenses remained roughly stable at $19.2 million and $10.7 million, respectively. Varseta-M (EpCAM ADC) was the largest R&D spend at $7.8 million, reflecting its role as the lead program.
CytomX raised significant capital through a March 2026 underwritten offering, issuing 45.99 million shares and 1.18 million pre-funded warrants for $234.2 million in net proceeds. As of March 31, 2026, it held $28.8 million in cash and cash equivalents and $317.9 million in short-term U.S. Treasury investments, giving total assets of $359.4 million and stockholders’ equity of $319.9 million.
CytomX Therapeutics (CTMX) reported Q3 2025 results marked by lower collaboration revenue and a quarterly loss as it reprioritized programs and completed a major equity raise. Revenue was $5.963 million, down from $33.432 million a year ago, reflecting wind-downs and timing across partnerships. The company posted a net loss of $14.229 million versus income of $5.736 million in Q3 2024.
Year to date, revenue totaled $75.538 million and net income was $9.142 million, aided by recognition of deferred revenue earlier in 2025. Cash and cash equivalents were $34.185 million and short-term investments $109.441 million at September 30, 2025. Total assets rose to $158.254 million and stockholders’ equity improved to $107.389 million, supported by a May underwritten offering of 76,923,076 shares at $1.30 per share for $93.4 million net proceeds.
Deferred revenue declined to $27.916 million, with remaining balances primarily tied to Astellas ($7.2 million), Moderna ($9.3 million) and Regeneron ($11.4 million). The company executed a restructuring in January (approximately 40% workforce reduction; $2.8 million charges) and is prioritizing CX‑2051 (EpCAM ADC) and CX‑801 (IFNα2b) while continuing multi-partner collaborations.
CytomX Therapeutics (CTMX) Q2-25 10-Q snapshot
Six-month collaboration revenue inched up 4% YoY to $69.6 million, buoyed by Astellas milestones and BMS research fees. Tight cost control (R&D –32% to $32.2 million; G&A flat at $16.1 million) flipped YTD operating loss into a $23.4 million net profit (vs. $7.3 million profit LY), largely from $61.8 million of deferred-revenue recognition tied to Amgen and BMS program terminations. Q2 revenue fell 26% YoY to $18.7 million, producing a modest $0.2 million quarterly loss.
Liquidity strengthened: cash, equivalents and Treasuries rose to $159.5 million (Dec-24: $101.9 million) on a $93.4 million May follow-on offering. Share count is 164.9 million (31 Jul 25). Stockholders’ equity swung to $119.9 million from a $(0.5) million deficit.
- Restructuring: 40 % workforce cut; $3.0 million charges booked.
- Pipeline: CX-2051 showed 28 % ORR (43 % at 10 mg/kg) in Phase 1 colorectal cancer; dose expansions ongoing. CX-801 monotherapy escalation at dose-level 4; Keytruda combo started.
- Collaborations: Amgen EGFR TCE and BMS CTLA-4 licenses ended; remaining deferred revenue $32.3 million expected through 2027.
- Balance-sheet risk: $4.2 million uncertain tax liability from California audit.